Drug intelligence / Profile preview

necitumumab + pembrolizumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of necitumumab, an EGFR antagonist monoclonal antibody, and pembrolizumab, a PD-1 inhibitor monoclonal antibody. This combination leverages dual mechanisms of action: necitumumab blocks EGFR signaling and induces antibody-dependent cell cytotoxicity, while pembrolizumab enhances T-cell immune response by blocking the PD-1 pathway. The combination has been studied primarily for non-small cell lung cancer (NSCLC), showing modest benefits in patients who progressed after platinum-based chemotherapy.

Targets

PDCD1 (Programmed cell death protein 1 receptor)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on necitumumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on necitumumab + pembrolizumab.

Explore the full profile